Inhibitory effect and mechanism of hirsuteine on NCI‑H1299 lung cancer cell lines

X Yun, H Qin, B Du, Y Peng, Y Liu… - Oncology …, 2023 - spandidos-publications.com
Traditionally, the bark of Uncaria rhynchophylla (UR) has been employed for the treatment of
hypertension, cancer, convulsions, haemorrhage, autoimmune disorders and other ailments …

Evolution of surgical treatment of metastatic spine tumors

PZ Sullivan, T Niu, JF Abinader, S Syed… - Journal of Neuro …, 2022 - Springer
Purpose The treatment of cancer has transformed over the past 40 years, with medical
oncologists, radiation oncologists and surgeons working together to prolong survival times …

Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A …

R Tomida, M Takahashi, Y Matsushita, T Kojima… - Clinical Genitourinary …, 2024 - Elsevier
Background To date, no studies have compared the treatment outcomes of second-line
therapies in patients with metastatic clear cell renal cell carcinoma (ccRCC). This study …

Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment

K Tada, K Daizumoto, M Takahashi, H Uehara… - IJU Case …, 2023 - Wiley Online Library
Introduction A case of multiple liver metastases of clear cell RCC with a significant response
to sunitinib as the fifth line after nivolumab is reported. Case presentation The patient was a …

Real‐world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST‐NIVO study): 36‐month follow‐up …

J Yonese, N Hinata, S Masui, Y Nakai… - … Journal of Urology, 2023 - Wiley Online Library
Objectives To examine the long‐term effectiveness of nivolumab monotherapy and following
subsequent therapies for metastatic renal cell carcinoma (mRCC) in Japanese real‐world …

[HTML][HTML] Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report

HP Wei, J Mao, ZL Hu - World Journal of Clinical Cases, 2022 - ncbi.nlm.nih.gov
BACKGROUND Apatinib is an orally bioavailable small-molecule receptor tyrosine kinase
inhibitor. In December 2014, the China Food and Drug Administration made it the first anti …